<DOC>
	<DOCNO>NCT00649168</DOCNO>
	<brief_summary>The objective study ass single-dose relative bioavailability Mylan Pharmaceuticals Inc. Novartis Pharmaceuticals Corporation ( Parlodel® ) 5 mg bromocriptine mesylate capsule , follow administration 10 mg dose , fed condition .</brief_summary>
	<brief_title>Fed Study ( Parlodel® ) Bromocriptine Mesylate Capsules 5 mg</brief_title>
	<detailed_description />
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<criteria>Healthy adult male female volunteer , 1845 year age Subjects continuous nonsmoker least 3 month prior first dose consistent moderate smoker ( few 10 cigarette per day ) least 3 month prior first dose Weighing least 60 kg male 52 kg female within normal range , accord accept normal value Body Mass Index chart ( BMI ) ( 18.0028.00 kg/m2 ) Medically healthy subject clinically normal laboratory profile 12lead ECG Females childbearing potential either sexually inactive ( abstinent ) 14 day prior first dose throughout study use one follow acceptable birth control method surgically sterile ( bilateral tubal ligation hysterectomy bilateral oophorectomy ) 6 month minimum IUD ( exclude hormonereleasingIUD ) place least 3 month throughout study barrier method ( condom diaphragm ) spermicide least 14 day prior first dose throughout study surgical sterilization partner ( vasectomy 6 month minimum ) In addition female subject childbearing potential advise remain sexually inactive keep birth control method least 3 day follow last dose Other birth control method may deem acceptable Postmenopausal woman amenorrhea least 2 year eligible . Males must use spermicidecontaining barrier method contraception prevent pregnancy female sexual partner screening , throughout entire study least 3 day follow last dose Give voluntary write informed consent participate study History presence significant cardiovascular pulmonary hepatic renal , hematologic gastrointestinal endocrine immunologic dermatologic neurologic psychiatric disease In addition history presence depression seizure history EEG abnormalities glaucoma hypermetropia frequent migraine episode alcoholism drug abuse within past year past psychotic maniac episode asthma chronic bronchitis bronchospastic condition peptic ulcer hypersensitivity idiosyncratic reaction bromocriptine ergot alkaloid relate compound hypersensitivity idiosyncratic reaction acetaminophen diphenhydramine metoclopramide diazepam phenothiazine relate compound subject test positive screening HIV , HbsAg HCV Subjects whose sit blood pressure le 110/60 mmHg screen less 100/55 mmHg prior dose period Subjects whose sit blood pressure 140/90 mmHg screen prior dose period Subjects whose pulse low 55 b.p.m . screen 50 b.p.m . prior dose period Female subject pregnant lactate Female subject take hormonal contraceptive hormonal replacement therapy ( include formulation , e.g . oral , transdermal , vaginal ) 28 day prior first dose throughout study Subjects use DepoProvera® levonorgestrel implant within 90 day prior first dose throughout study Subjects receive substance monoamine oxidase inhibitor ( MAOI ) activity within 28 day prior first dose Subjects food allergy , problem galactose intolerance glucosegalactose malabsorption , restriction , opinion Principal Investigator , could contraindicate subject 's participation study Subjects special diet ( whatever reason ) 28 day prior first dose throughout study Subjects donate 50 499 mL blood within 30 day 499 mL within 56 day prior first dose Subjects , completion study would donate excess 500 mL blood 14 day 1500 mL blood 180 day 2500 mL blood 1 year Subjects participate another clinical trial within 28 day prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>